253 related articles for article (PubMed ID: 29681457)
21. The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase.
Song LN; Silva J; Koller A; Rosenthal A; Chen EI; Gelmann EP
Mol Cancer Res; 2015 May; 13(5):913-22. PubMed ID: 25777618
[TBL] [Abstract][Full Text] [Related]
22. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
23. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.
Burdelski C; Fitzner M; Hube-Magg C; Kluth M; Heumann A; Simon R; Krech T; Clauditz T; Büscheck F; Steurer S; Wittmer C; Hinsch A; Luebke AM; Jacobsen F; Minner S; Tsourlakis MC; Beyer B; Steuber T; Thederan I; Sauter G; Izbicki J; Schlomm T; Wilczak W
Neoplasia; 2017 Apr; 19(4):279-287. PubMed ID: 28282546
[TBL] [Abstract][Full Text] [Related]
25. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.
Iwata T; Schultz D; Hicks J; Hubbard GK; Mutton LN; Lotan TL; Bethel C; Lotz MT; Yegnasubramanian S; Nelson WG; Dang CV; Xu M; Anele U; Koh CM; Bieberich CJ; De Marzo AM
PLoS One; 2010 Feb; 5(2):e9427. PubMed ID: 20195545
[TBL] [Abstract][Full Text] [Related]
26. Germ-line mutation of NKX3.1 cosegregates with hereditary prostate cancer and alters the homeodomain structure and function.
Zheng SL; Ju JH; Chang BL; Ortner E; Sun J; Isaacs SD; Sun J; Wiley KE; Liu W; Zemedkun M; Walsh PC; Ferretti J; Gruschus J; Isaacs WB; Gelmann EP; Xu J
Cancer Res; 2006 Jan; 66(1):69-77. PubMed ID: 16397218
[TBL] [Abstract][Full Text] [Related]
27. Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.
Zumsteg ZS; Spratt DE; Romesser PB; Pei X; Zhang Z; Kollmeier M; McBride S; Yamada Y; Zelefsky MJ
J Urol; 2015 Dec; 194(6):1624-30. PubMed ID: 26165583
[TBL] [Abstract][Full Text] [Related]
28. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
[TBL] [Abstract][Full Text] [Related]
29. Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers.
Lotan TL; Torres A; Zhang M; Tosoian JJ; Guedes LB; Fedor H; Hicks J; Ewing CM; Isaacs SD; Johng D; De Marzo AM; Isaacs WB
Oncotarget; 2017 Apr; 8(14):22772-22782. PubMed ID: 28186998
[TBL] [Abstract][Full Text] [Related]
30. Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers.
Müller J; Ehlers A; Burkhardt L; Sirma H; Steuber T; Graefen M; Sauter G; Minner S; Simon R; Schlomm T; Michl U
Int J Cancer; 2013 Mar; 132(6):1333-40. PubMed ID: 22886792
[TBL] [Abstract][Full Text] [Related]
31. Intratumoral heterogeneity and subclonal diversification of early breast cancer.
Yates LR
Breast; 2017 Aug; 34 Suppl 1():S36-S42. PubMed ID: 28666921
[TBL] [Abstract][Full Text] [Related]
32. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers.
Voeller HJ; Augustus M; Madike V; Bova GS; Carter KC; Gelmann EP
Cancer Res; 1997 Oct; 57(20):4455-9. PubMed ID: 9377551
[TBL] [Abstract][Full Text] [Related]
33. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
34. The loss of NKX3.1 expression in testicular--and prostate--cancers is not caused by promoter hypermethylation.
Lind GE; Skotheim RI; Fraga MF; Abeler VM; Henrique R; Saatcioglu F; Esteller M; Teixeira MR; Lothe RA
Mol Cancer; 2005 Feb; 4(1):8. PubMed ID: 15691383
[TBL] [Abstract][Full Text] [Related]
35. Anisometric cell lipoma: Insight from a case series and review of the literature on adipocytic neoplasms in survivors of retinoblastoma suggest a role for RB1 loss and possible relationship to fat-predominant ("fat-only") spindle cell lipoma.
Agaimy A
Ann Diagn Pathol; 2017 Aug; 29():52-56. PubMed ID: 28807343
[TBL] [Abstract][Full Text] [Related]
36. Genetic variants in RhoA and ROCK1 genes are associated with the development, progression and prognosis of prostate cancer.
Liu K; Li X; Wang J; Wang Y; Dong H; Li J
Oncotarget; 2017 Mar; 8(12):19298-19309. PubMed ID: 28184030
[TBL] [Abstract][Full Text] [Related]
37. ETS1 regulates NKX3.1 5' promoter activity and expression in prostate cancer cells.
Preece DM; Harvey JM; Bentel JM; Thomas MA
Prostate; 2011 Mar; 71(4):403-14. PubMed ID: 20842667
[TBL] [Abstract][Full Text] [Related]
38. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression.
Bowen C; Bubendorf L; Voeller HJ; Slack R; Willi N; Sauter G; Gasser TC; Koivisto P; Lack EE; Kononen J; Kallioniemi OP; Gelmann EP
Cancer Res; 2000 Nov; 60(21):6111-5. PubMed ID: 11085535
[TBL] [Abstract][Full Text] [Related]
39. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features.
Aslan G; Irer B; Tuna B; Yorukoglu K; Saatcioglu F; Celebi I
Pathol Res Pract; 2006; 202(2):93-8. PubMed ID: 16413692
[TBL] [Abstract][Full Text] [Related]
40. Stabilization of the prostate-specific tumor suppressor NKX3.1 by the oncogenic protein kinase Pim-1 in prostate cancer cells.
Padmanabhan A; Gosc EB; Bieberich CJ
J Cell Biochem; 2013 May; 114(5):1050-7. PubMed ID: 23129228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
